Literature DB >> 21197158

Commercial Licensing of HIV-1 Protease: Applications of the NIH Research Tools Policy.

George H Keller, Steven M Ferguson.   

Abstract

Licensing of the HIV-1 protease gene by the NIH Office of Technology Transfer (OTT) provides an example of the effective use of the principles of the NIH Research Tools Policy, which was designed to provide broad access to important biomedical technologies. The OTT licensing experience is presented in detail as it was applied to research reagents, diagnostics and drug development to thus enhance the overall development process for a wide variety of medical products.

Entities:  

Year:  2009        PMID: 21197158      PMCID: PMC3013055     

Source DB:  PubMed          Journal:  J Biolaw Bus        ISSN: 1095-5127


  5 in total

Review 1.  High-throughput crystallography for lead discovery in drug design.

Authors:  Tom L Blundell; Harren Jhoti; Chris Abell
Journal:  Nat Rev Drug Discov       Date:  2002-01       Impact factor: 84.694

Review 2.  Distribution and licensing of drug discovery tools--NIH perspectives.

Authors:  Steven M Ferguson; J P Kim
Journal:  Drug Discov Today       Date:  2002-11-01       Impact factor: 7.851

3.  Developing products for personalized medicine: NIH Research Tools Policy applications.

Authors:  Ranjan Gupta; Jp Kim; Jack Spiegel; Steven M Ferguson
Journal:  Per Med       Date:  2004-12-01       Impact factor: 2.512

4.  Primary structure and processing of gag and env gene products of human T-cell leukemia viruses HTLV-ICR and HTLV-IATK.

Authors:  S Oroszlan; T D Copeland
Journal:  Curr Top Microbiol Immunol       Date:  1985       Impact factor: 4.291

5.  Products, Partners & Public Health: Transfer of Biomedical Technologies from the U.S. Government.

Authors:  Steven M Ferguson
Journal:  J Biolaw Bus       Date:  2002
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.